In recent years, an increasing number of people who used Tepezza for thyroid eye disease have encountered an alarming outcome: permanent hearing impairments. These include hearing loss and tinnitus.
These individuals are now turning to the legal system for remedies, filing lawsuits against Horizon Therapeutics, the manufacturer of Tepezza. The lawsuits allege that Horizon failed to adequately warn doctors and patients about the potential health risks associated with the drug.
In this article, we will dive into the unfolding narrative of Tepezza lawsuits and the path from the health risk to seeking legal recourse.
Tepezza: A Breakthrough Treatment
Tepezza, hailed as a groundbreaking treatment for thyroid eye disease, gained FDA approval in January 2020. However, clinical trials revealed that approximately 10% of patients experienced hearing issues.
However, the Endocrine Society shared a Stanford University study, which indicates that the risk of hearing problems could be as high as 65%. Despite these concerning results, Tepezza’s label did not warn patients or medical practitioners about the potential for permanent hearing loss or tinnitus.
The Legal Battle
As cases of Tepezza-related hearing issues have mounted, affected individuals have opted for legal recourse. Those who have suffered permanent hearing loss or tinnitus after taking Tepezza are pursuing legal action.
They have filed a Tepezza hearing loss lawsuit that aims to seek compensation for medical expenses, pain and suffering, and lost wages. Filing lawsuits also serves as a crucial means of alerting other potential Tepezza users to the associated risks.
According to TorHoerman Law, these lawsuits claim that Horizon Therapeutics’ failure to provide adequate warnings about potential auditory risks led to irreversible harm. These legal actions are in their early stages, with no trials scheduled or court-approved settlements as of July 2023.
According to an update by Aboutlawsuits, the plaintiffs initiated a motion to consolidate Tepezza cases into multidistrict litigation (MDL). Subsequently, the MDL panel decided to centralize the cases in the Northern District of Illinois under the jurisdiction of Judge Thomas M. Durkin. This consolidation streamlines legal proceedings and facilitates efficient management of complex litigation.
Qualifying for a Tepezza Lawsuit
Individuals who have experienced permanent or persistent hearing loss or tinnitus after taking Tepezza may be eligible to file a lawsuit. Attorneys will typically inquire about the timing and duration of Tepezza use, the number of treatments received, and the type of hearing problems encountered. It is crucial for those considering legal action to consult a Tepezza attorney promptly due to the time limits for filing a case.
Horizon’s Updated Warning Label
In a pivotal development reported by MedTruth, Horizon Therapeutics added a warning about hearing impairment to Tepezza’s label in July 2023. This crucial alteration was a response to mounting evidence and legal pressure, highlighting the manufacturer’s acknowledgment of the auditory risks associated with the drug.
The newly added warning on the label serves as a long-awaited acknowledgment of the concerns raised by plaintiffs and medical experts alike. It underscores the importance of vigilance when it comes to monitoring patients’ hearing throughout their Tepezza treatment journey.
The updated label explicitly advises healthcare professionals to assess patients’ hearing before initiating treatment. It also highlights the importance of monitoring it during treatment and considers the balance between the potential benefits and risks associated with Tepezza.
What’s Next for Tepezza Lawsuits?
Tepezza lawsuits represent a significant legal battleground as affected individuals seek justice for the irreversible hearing impairments they have endured. With cases consolidated in an MDL, the multidistrict litigation panel’s decision to move proceedings to Illinois sets the stage for the next phase: discovery.
The outcome of the Tepezza lawsuits has the potential to influence the pharmaceutical industry’s approach to drug labeling, patient education, and accountability. As more individuals step forward to file lawsuits and share their experiences, the legal landscape surrounding Tepezza will continue to evolve.
This evolution is expected to shed light on the drug’s risks and the responsibility of pharmaceutical manufacturers to adequately inform patients and medical professionals.
The surge in Tepezza-related lawsuits against Horizon Therapeutics reflects the profound impact of alleged inadequate warnings on patients’ lives. The multidistrict litigation consolidation streamlines the quest for justice, while the updated label points to the critical need for comprehensive risk communication.
This legal battle underscores the far-reaching implications of pharmaceutical transparency and accountability, amplifying the urgency for ethical and vigilant information dissemination. As cases evolve, it becomes clear that beyond financial compensation, these lawsuits emphasize the pivotal role of pharmaceutical companies in safeguarding patient well-being.